Madrigal Pharmaceuticals (MDGL) PT Lowered to $186 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Citi analyst Joel Beatty lowered the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $186.00 (from $200.00) reflecting the analyst's belief that the ph3 agent, Resmetirom, has the profile to be one of the more widely used NASH drugs but he cut his probability-unadjusted 2026 sales estimate to $1.9B (from $2.1B).
The analyst is expecting a number of ph2b readouts from competitors between now and MDGL’s ph3 results in ~mid 2021 that should reflect increasing competition. The analyst stated "Some of these competing drugs will likely be successful and go on to compete for market share, in our view". No change to the Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Honeywell International (HON) PT Lowered to $261 at BMO Capital
- CACI International (CACI) PT Lowered to $823 at UBS
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
